ATYPICAL RESPONDERS LANDSCAPE REVIEW ∙ OCTOBER, 2017 42 1. NCI and the Precision Medicine Initiative® . 2. Conley, B.A., et al., The NCI exceptional responders initiatives: Initial feasibility result, in American Assocation of Cancer Research 106th Annual Meeting. 2015: Philadelphia, PA. p. 612. 3. Wagle, N., et al., The metastatic breast cancer project: A national direct-to-patient research initiative to accelerate genomics research, in San Antonio Breast Cancer Symposium. 2015: San Antonio, Texas. 4. Wagle N, P.C., Ilzarbe M, Van Allen EM, Frank E, Oh C, Krevalin M, Lloyd M, Anderka K, Kryukov G, Boehm JS, Winer E, Lander ES, Golub TR, The metastatic breast cancer project: A national direct-to-patient research initiative to accelerate genomics research. San Antonio Breast Cancer Symposium, 2015. 5. Zardavas, D., et al., The AURORA initiative for metastatic breast cancer. Br J Cancer, 2014. 111(10): p. 1881-7. 6. Hyman, D.M., et al., Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discov Today, 2015. 20(12): p. 1422-8. 7. Cheng, D.T., et al., Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. J Mol Diagn, 2015. 17(3): p. 251-64. 8. Subbiah, I.M. and V. Subbiah, Exceptional responders: in search of the science behind the miracle cancer cures. Future Oncol, 2015. 11(1): p. 1-4. 9. Chau, N.G. and J.H. Lorch, Exceptional Responders Inspire Change: Lessons for Drug Development From the Bedside to the Bench and Back. Oncologist, 2015. 20(7): p. 699- 701. 10. Levin, M.K., et al., Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine. Cancer Med, 2015. 4(8): p. 1289-93. 11. Wagle, N., et al., Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med, 2014. 371(15): p. 1426-33. 12. Van Allen, E.M., et al., The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov, 2014. 4(1): p. 94-109. References